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Blood low-density lipoprotein (LDL) cholesterol, high-density lipoprotein (HDL) cholesterol and triglyceride levels are risk factors
for cardiovascular disease. To dissect the polygenic basis of these traits, we conducted genome-wide association screens in 19,840
individuals and replication in up to 20,623 individuals. We identified 30 distinct loci associated with lipoprotein concentrations
(each with P o 5  108), including 11 loci that reached genome-wide significance for the first time. The 11 newly defined loci
include common variants associated with LDL cholesterol near ABCG8, MAFB, HNF1A and TIMD4; with HDL cholesterol near
ANGPTL4, FADS1-FADS2-FADS3, HNF4A, LCAT, PLTP and TTC39B; and with triglycerides near AMAC1L2, FADS1-FADS2-FADS3
and PLTP. The proportion of individuals exceeding clinical cut points for high LDL cholesterol, low HDL cholesterol and high
triglycerides varied according to an allelic dosage score (P o 1015 for each trend). These results suggest that the cumulative
effect of multiple common variants contributes to polygenic dyslipidemia.
Recent genome-wide association studies (GWASs) have localized
common DNA sequence variants that contribute to many human
phenotypes1. The success of this approach has been parti-
cularly notable for blood lipoprotein levels. We and others recently
reported that at least 19 genetic loci harbor common DNA sequence
variants associated with blood LDL cholesterol, HDL cholesterol
and/or triglycerides2–6. Those loci consist of genes previously shown
to affect lipoprotein metabolism in humans, as well as eight loci
that were newly reported at the time. However, each variant con-
ferred a modest effect, and, together, the variants explained only a
small fraction (B5%) of interindividual variability in lipo-
protein levels. These observations suggested that additional loci
harboring lipid-associated DNA sequence variants could be
identified with larger samples and improved statistical power for
gene discovery.
RESULTS
Meta-analysis and replication of genome-wide association scans
We conducted a meta-analysis of seven GWASs of blood lipoprotein
and lipid phenotypes, and we conducted follow-up replication ana-
lyses in up to five additional studies (Table 1; see Supplementary
Fig. 1 online for study design). The Framingham Heart Study (FHS), a
prospective epidemiologic cohort established in 1948, represents the
largest GWAS sample7. Among the three generations of FHS partici-
pants who have been enrolled, we focused on second- and third-
generation participants with fasting blood lipid phenotypes8,9. The
power of the sample was indicated by the observation that for each of
eight SNPs recently associated with lipid levels (near SORT1 for LDL
cholesterol; MMAB-MVK and GALNT2 for HDL cholesterol; and
GCKR, TRIB1, MLXIPL, NCAN and ANGPTL3 for triglycerides),
association results in the FHS confirmed our earlier reports
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(Po 0.05; Supplementary Table 1 online)3,4. Replication consisted of
the same allele at the same SNP associated in the same direction.
To the FHS data for 7,423 individuals, we added GWAS data for
3,733 individuals of European ancestry from the London Life Sciences
Prospective Population Cohort (LOLIPOP), Supple´mentation en
Vitamines et Mine´raux Antioxydants (SUVIMAX) and Invecchiare
in Chianti (InCHIANTI) studies (Supplementary Methods online)
and 8,684 individuals from our previous studies of the Diabetes
Genetics Initiative (DGI)2,3, Finland–United States Investigation
of NIDDM Genetics (FUSION)4 and SardiNIA Study of Aging
(SardiNIA)4 samples, to bring the total stage 1 sample size to 19,840
individuals (Supplementary Fig. 1).
We used genotyped SNPs from each study and phased chromo-
somes from the HapMap sample of Utah residents with ancestry from
northern and western Europe (CEU) to impute autosomal SNPs with
minor allele frequency 41%. A total ofB2.6 million SNPs that were
directly genotyped or imputed were tested for association with
lipoprotein traits. Association statistics for each marker from each
of the seven studies were combined using a weighted z statistic–based
meta-analysis4. Genomic control parameters for the meta-analysis
Table 2 Genetic loci where common polymorphisms are associated with blood lipoprotein concentrations
FHS effect size estimatesa
Trait Chr. SNP
P for combined
stage 1 + 2
association
Combined
stage 1 + 2
sample size
Associated interval
size, kb (no. of genes
within interval)
Gene(s) of interest
within or near
associated interval
Major allele,
minor allele (MAF)
Effect size for
minor allele (s.e.m.)b
Newly identified common SNPsd
LDL 2p21 rs6544713 2  1020 23,456 52 (2) ABCG8 C, T (0.32)c 0.15 (0.02)
LDL 5q23 rs1501908 1  1011 27,280 153 (2) TIMD4-HAVCR1 C, G (0.37) –0.07 (0.02)
LDL 20q12 rs6102059 4  109 28,895 104 (0) MAFB C, T (0.32)c –0.06 (0.02)
LDL 12q24 rs2650000 2  108 39,340 112 (3) HNF1A C, A (0.36) 0.07 (0.02)
HDL 11q12 rs174547 2  1012 40,330 84 (5) FADS1-FADS2-FADS3 T, C (0.33) –0.09 (0.02)
HDL 16q22 rs2271293 9  1013 31,946 620 (25) LCAT G, A (0.11) 0.07 (0.03)
HDL 9p22 rs471364 3  1010 40,414 55 (1) TTC39B T, C (0.12) –0.08 (0.03)
HDL 20q13 rs1800961 8  1010 30,714 24 (1) HNF4A C, T (0.03) –0.19 (0.05)
HDL 20q13 rs7679 4  109 40,248 141 (5) PLTP T, C (0.19) –0.07 (0.02)
HDL 19p13 rs2967605 1  108 35,151 155 (5) ANGPTL4 C, T (0.16)c –0.12 (0.04)
TG 11q12 rs174547 2  1014 38,846 84 (5) FADS1-FADS2-FADS3 T, C (0.33) 0.06 (0.02)
TG 20q13 rs7679 7  1011 38,561 141 (5) PLTP T, C (0.19) 0.07 (0.02)
TG 8p23 rs7819412 3  108 33,336 550 (4) XKR6-AMAC1L2 A, G (0.48) –0.04 (0.02)
Loci with definitive prior association evidence
LDL 1p13 rs12740374 2  1042 19,648 85 (4) CELSR2, PSRC1, SORT1 G, T (0.21)c –0.23 (0.02)
LDL 2p24 rs515135 5  1029 19,648 214 (1) APOB C, T (0.20)c –0.16 (0.02)
LDL 19q13 rs4420638 4  1027 11,881 79 (4) APOE-APOC1-APOC4-APOC2 A, G (0.16)c 0.29 (0.06)
LDL 19p13 rs6511720 2  1026 19,648 30 (1) LDLR G, T (0.10)c –0.26 (0.04)
LDL 5q13 rs3846663 8  1012 19,648 476 (4) HMGCR C, T (0.38) 0.07 (0.02)
LDL 19p13 rs10401969 2  108 19,648 503 (18) NCAN, CILP2, PBX4 T, C (0.06)c –0.05 (0.04)
LDL 1p32 rs11206510 4  108 19,629 16 (1) PCSK9 T, C (0.19) –0.09 (0.02)
HDL 16q13 rs173539 4  1075 19,794 36 (1) CETP C, T (0.32)c 0.25 (0.02)
HDL 8p21 rs12678919 2  1034 19,794 126 (1) LPL A, G (0.10)c 0.23 (0.03)
HDL 15q22 rs10468017 8  1023 19,794 47 (0) LIPC C, T (0.30)c 0.10 (0.02)
HDL 18q21 rs4939883 7  1015 19,785 128 (1) LIPG C, T (0.17) –0.14 (0.02)
HDL 11q23 rs964184 1  1012 19,794 138 (3) APOA1-APOC3-APOA4-APOA5 C, G (0.14)c –0.17 (0.03)
HDL 12q24 rs2338104 1  1010 19,793 315 (5) MMAB, MVK G, C (0.45) –0.07 (0.02)
HDL 9q31 rs1883025 1  109 19,371 48 (1) ABCA1 C, T (0.26)c –0.08 (0.02)
HDL 1q42 rs4846914 4  108 19,794 53 (1) GALNT2 A, G (0.40) –0.05 (0.02)
TG 11q23 rs964184 4  1062 19,840 138 (3) APOA1-APOC3-APOA4-APOA5 C, G (0.14)c 0.30 (0.03)
TG 8p21 rs12678919 2  1041 19,840 126 (1) LPL A, G (0.10)c –0.25 (0.03)
TG 2p23 rs1260326 2  1031 19,840 465 (22) GCKR C, T (0.45)c 0.12 (0.02)
TG 8q24 rs2954029 3  1019 19,840 35 (0) TRIB1 A, T (0.44)c –0.11 (0.02)
TG 7q11 rs714052 3  1015 19,840 254 (5) MLXIPL A, G (0.12)c –0.16 (0.03)
TG 2p24 rs7557067 9  1012 19,840 149 (1) APOB A, G (0.22)c –0.08 (0.02)
TG 19p13 rs17216525 4  1011 19,840 448 (15) NCAN, CILP2, PBX4 C, T (0.07)c –0.11 (0.03)
TG 1p31 rs10889353 3  107 19,834 305 (3) ANGPTL3 A, C (0.33)c –0.05 (0.02)
Chr., chromosome; MAF, minor allele frequency.
aEffect size and direction from the FHS, the largest of the stage 1 studies, are presented for illustrative purposes. Alleles for the SNP on the forward strand of the human genome reference
sequence (NCBI build 36.2) are shown, and the minor allele at each SNP was modeled. bEffect size shown is b-coefficient, which represents change in lipid levels measured in s.d. units (in a sex-
stratified analysis after adjustment for age, age2 and ten ancestry-informative principal components) per copy of the allele modeled. cResults for these SNPs are derived from imputed SNP data.
dFor five of these loci (TIMD4-HAVCR1, MAFB, FADS1-FADS2-FADS3, TTC39B and XKR6-AMAC1L2), there is no prior statistical evidence for association with blood lipoprotein concentrations. For
the remaining six, there is at least some modest statistical evidence for common SNPs. For these six loci, we provide definitive evidence for common SNPs.
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of the stage 1 studies were low, at 1.03 for LDL cholesterol, 1.04
for HDL cholesterol and 1.03 for triglycerides, suggesting little
residual confounding caused by population stratification or un-
modeled relatedness.
In the meta-analysis of seven stage 1 studies, 25 unique loci
harbored variants associated with LDL cholesterol, HDL cholesterol
or triglycerides at a significance level of Po 5  108 (corresponding
to P o 0.05 after adjusting for B1 million independent tests, the
estimated multiple testing burden in GWAS of individuals of Eur-
opean ancestry10). To evaluate these and other less significantly
associated SNPs from stage 1, we genotyped SNPs in a maximum of
20,623 individuals from five stage 2 studies: Malmo¨ Diet and Cancer
Study (MDC)11, FINRISK97 (ref. 12), FUSION stage 2 (ref. 13),
Metabolic Syndrome in Men (METSIM) and International Study of
Infarct Survival (ISIS)14 (Table 1 and Supplementary Fig. 1). These
SNPs were selected to focus on loci that had not previously been
associated with our lipoprotein phenotypes (see Methods).
In the analysis including stage 1 and stage 2 studies, SNPs at 30 loci
were convincingly associated (P o 5  108) with LDL cholesterol,
HDL cholesterol or triglycerides, including 11 loci that reached
genome-wide significance for the first time (Table 2 and Fig. 1).
Each of the loci reached P o 1  105 in stage 1 and P o 0.05 in
stage 2 (Supplementary Table 2 online). The 11 loci definitively
identified in this study included genes whose function in humans has
previously been studied (ABCG8 (ref. 15); ANGPTL4 (ref. 16);
FADS1-FADS2-FADS3 (ref. 17); HNF4A18; LCAT19; PLTP20; and
HNF1A21) and genes whose function in humans is poorly
understood (TTC39B, TIMD4-HAVCR1,
XKR6, AMAC1L2 and MAFB; Fig. 2).
We confirmed these 30 association signals
by carrying out a uniform analysis strategy
for all studies and then applying an inverse-
variance weighted meta-analysis (Supple-
mentary Table 3 online). This analysis also
allowed us to test for heterogeneity in effect
sizes across studies. No significant evidence
for heterogeneity was detected for any of the
newly identified loci (Supplementary Tables
4–6 online).
Lipid-associated SNPs and gene
expression in human liver
The associated SNP at 1 of the 11 new loci
was a nonsynonymous coding variant,
HNF4A rs1800961 (T130I, 3% frequency),
and the remaining 10 new associated SNPs
were noncoding. We therefore explored
whether lipid-associated variants might influ-
ence gene expression as cis-acting regulators
of nearby genes. We genotyped DNA and
profiled RNA expression of 439,000 tran-
scripts in 957 human liver tissue samples22.
We conducted expression quantitative trait
locus analyses relating the SNPs in Table 2
with liver transcripts located within 500 kb to
either side of the associated SNP (Table 3).
Together, the lipoprotein association data and
the expression quantitative trait locus ana-
lyses highlighted several biological insights.
For example, among five genes at the 20q13
locus for HDL cholesterol and triglycerides,
expression of PLTP was associated with rs7679 (P ¼ 6  1017;
Table 3). The rs7679 allele associated with higher PLTP transcript levels
was also associated with higher HDL cholesterol and lower triglycerides
(Tables 2 and 3). This is consistent with prior work in mice showing
that Pltp overexpression leads to higher HDL cholesterol23, whereas
targeted deletion leads to lower HDL cholesterol24. Consistency
between the direction of effect on transcript levels and lipoprotein
concentration was also evident at the LIPC locus. In agreement with
earlier studies in which lower hepatic lipase activity and higher HDL
cholesterol were associated with LIPC promoter variants25, the minor T
allele at LIPC rs10468017 was associated with lower LIPC expression in
our study (P ¼ 2  1018; Table 2) and increased HDL cholesterol
(P ¼ 8  1023; Table 3).
Another strong signal mapped to a cluster of three fatty acid
desaturase genes (FADS1-FADS2-FADS3) on 11q12 (Fig. 2e). The
cluster showed association with both HDL cholesterol and triglycer-
ides (Table 2), and the expression quantitative trait locus data
suggested that the associated SNP modulates expression of FADS1
and FADS3 (Table 3). The allele associated with increased FADS1 and
FADS3 expression led to higher HDL cholesterol and lower triglycer-
ides. Fatty acid desaturases convert polyunsaturated fatty acids into
cell signaling metabolites, including arachidonic acid. SNPs at this
locus have been previously related to levels of arachidonic acid in
serum phospholipids and red blood cell plasma membranes17. In
addition, dietary omega-3 polyunsaturated fatty acids—a key sub-
strate for FADS1—are known to lower plasma triglycerides, possibly
by decreasing very-low-density lipoprotein secretion26.
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Figure 1 Summary of genome-wide association results for LDL cholesterol, HDL cholesterol and
triglycerides from stage 1. (a–c) Chromosome number versus –log10 P values for LDL cholesterol (a),
HDL cholesterol (b) and triglycerides (c). Green, 11 newly identified loci; blue, previously reported loci;
gray, loci not subjected to follow-up; red, loci that did not replicate. (d–f) Quantile-quantile plot for test
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Figure 2 Regional plots of 11 confirmed
associations. (a–k) Association results for SNPs
from stage 1 (–log10 P value) as a function of
genomic distance (chromosomal position from
National Center for Biotechnology Information
build hg17) for ABCG8 (a), TIMD4-HAVCR1 (b),
MAFB (c), HNF1A (d), FADS1-FADS2-FADS3 (e),
LCAT (f), TTC39B (g), HNF4A (h), PLTP (i),
ANGPTL4 (j) and XKR6-AMAC1L2 (k). Top three
lines show genomic coverage at the locus, with
each vertical tick representing directly genotyped
(Illumina (Illu317k) or Affymetrix (Affy500k)
platforms) or imputed SNPs. Purple diamonds
indicate SNP at each locus with the strongest
stage 1 association evidence. Each circle represents a SNP, with the color of the circle indicating the correlation between that SNP and the best stage 1
SNP at the locus (purple diamond). Pcombined values indicate association evidence for the SNP based on the combined stage 1 and 2 data. In most cases,
the best stage 1 SNP at the locus (purple diamond) was taken forward to stage 2; however, alternate SNPs (red or orange diamonds) were taken forward at
two loci (HNF1A and PLTP). Light blue lines indicate estimated recombination hot spots in HapMap. Bottom panel shows genes at each locus as annotated
in the UCSC Genome Browser Annotation Database as of September 16, 2008. Gray bar indicates associated interval spanning the SNP taken forward to
stage 2. Associated intervals were determined as described in Methods. TG, triglyceride.
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At 9p22, an HDL-associated SNP was associated with expression of
tetratricopeptide repeat domain 39B (TTC39B; P ¼ 3  1010 for
genotype–HDL cholesterol association and P ¼ 3  108 for
genotype-expression association; Fig. 2g and Tables 2 and 3). The
allele associated with lower TTC39B transcript levels was also asso-
ciated with higher HDL cholesterol. Tetratricopeptides, in general,
seem to function in protein-protein interactions27, but TTC39B
presently has no annotated function in humans.
Genes causing mendelian syndromes also harbor common SNPs
Among the other loci to reach genome-wide significance, ABCG8 and
LCAT have been shown to cause mendelian forms of dyslipidemia28,29
(Fig. 2a,f). Loss-of-function mutations at ABCG8 and LCAT lead to
sitosterolemia and fish-eye disease, respectively. Common SNPs at
ABCG8 and LCAT have been studied for association with plasma LDL
and HDL cholesterol, respectively. In our study, common variants at
both loci reached genome-wide significance for the first time (Table 2).
For example, we found the previously studied ABCG8 D19H variant to
be associated with LDL cholesterol (rs11887534, P ¼ 1  1011) and
found an even stronger common variant signal, a SNP in intron 2 of
ABCG8 (rs6544713, 0.15 s.d. unit change per copy, P ¼ 2  1029;
r2 ¼ 0.02 with ABCG8 D19H). Both D19H and a proxy for ABCG8
rs6544713 (rs4299376, r2 ¼ 1) were recently shown to affect risk for
cholesterol gallstone disease30; for both the coding and intronic
variants, the allele corresponding to lower plasma LDL cholesterol in
the present study has been associated with higher risk of gallstones.
The observed signals at ABCG8 and LCAT further strengthen the
connection between loci for mendelian dyslipidemic syndromes and
those with common variants of modest effect. For at least 11 of the 30
loci in Table 2 (ABCG8, LCAT, APOB, APOE, LDLR, PCSK9, CETP,
LPL, LIPC, APOA5 and ABCA1), a biologically relevant lipoprotein
gene was implicated not only by common variants (45% frequency)
but also by low-frequency variants (0.5%–5% frequency) and/or rare
mutations (variants unique to individual families).
Another connection between signals identified here and rare men-
delian disorders occurred for HNF4A and HNF1A, two causes of
maturity-onset diabetes of the young (Fig. 2d,h). Both genes encode
hepatic nuclear transcription factors that regulate numerous target
genes involved in lipoprotein metabolism, including apolipoproteins,
cholesterol synthesis enzymes and bile acid transporters31. Although
mice lacking either Hnf4a or Hnf1a have altered plasma cholesterol
levels32,33, there has been only modest evidence to date connecting these
genes to either HDL or LDL cholesterol concentrations in humans18,21.
Other validated loci
At ANGPTL4, we found that a common variant (rs2967605, 16%
frequency, P ¼ 1  108 for stages 1 and 2) was strongly associated
with HDL cholesterol but not in linkage disequilibrium with a
previously reported low-frequency variant (ANGPTL4 E40K, 3%
frequency, r2o 0.01 with rs2967605)16. The gene is a strong mechan-
istic candidate because ANGPTL4 inhibits lipoprotein lipase in mice34.
Among the novel loci, the 8p23 region associated with triglycerides
contained one gene of particular interest, AMAC1L2, which encodes
acyl-malonyl condensing enzyme 1–like 2 (Fig. 2k) in bacteria, acyl-
malonyl condensing enzyme catalyzes fatty acid synthesis35. At the
5q23 and 20q12 loci associated with LDL cholesterol, the mechanism
of action is less clear. At 5q23, the associated interval spanned two
genes, TIMD4 and HAVCR1 (also known as TIMD1; Fig. 2b). TIMD4
and HAVCR1 were recently identified as phosphatidylserine receptors
on macrophages that facilitate the engulfment of apoptotic cells36, and
HAVCR1 is annotated as a target for the transcription factor HNF1A31.
At 20q12, the gene nearest to the associated SNP is MAFB (Fig. 2c), a
transcription factor shown to interact with LDL-receptor–related
protein37. How genes at these two loci impact LDL cholesterol remains
to be defined.
Specialized lipid phenotypes
To define the full spectrum of phenotypic consequences of lipid
variants at 30 distinct loci, we studied the association of each index
SNP with 21 specialized lipid phenotypes measured in FHS second-
generation participants (Supplementary Table 7 online). These phe-
notypes included apolipoproteins APOA-I, APOB, APOC-III and
APOE; low-, high-, intermediate- and very low–density lipoprotein
particle concentrations, as measured by nuclear magnetic resonance;
Table 3 Cis-acting association of validated lipid polymorphisms with transcript levels in human liver
Lipid-associated
SNP
Lipid
trait Locus
Gene(s) of
interest in
associated
genomic interval
Transcript
gene symbol
No. of liver
samples
Major, minor alleles for
SNP associated with
liver transcript level
P for association
evidence with liver
transcript level
Allele modeled,
direction of effect on
transcript level, direction
of effect on lipid level
rs7679 HDL 20q13 PLTP PLTP 885 T, C 6  10–17 T, +, +
TG T, +, –
rs10468017 HDL 15q22 LIPC LIPC 950 C, T 2  10–18 T, –, +
ALDH1A2 943 C, T 2  10–9 T, –, +
rs174547a HDL 11q12 FADS1-FADS2-FADS3 FADS1 943 T, C 5  10–35 T, +, +
TG T, +, –
HDL FADS3 925 T, C 1  10–8 T, +, +
TG T, +, –
rs471364 HDL 9p22 TTC39B TTC39B 955 T, C 3  10–8 T, –, +
rs12740374b LDL 1p13 CELSR2, PSRC1, SORT1 SORT1 946 T, C 4  10–272 T, –, +
PSRC1 T, C 2  10–241 T, –, +
CELSR2 T, C 6  10–80 T, –, +
rs2338104c HDL 12q24 MMAB, MVK MMAB 957 A, G 4  10–43 G, –, +
rs10889353 TG 1p31 ANGPLT3 DOCK7 952 A, C 2  10–27 C, +, –
ANGPTL3 903 A, C 2  10–11 C, +, –
aSNP associated with liver transcript level was rs102275 (r2 ¼ 1 with rs174547 in HapMap CEU). bSNP associated with liver transcript level was rs646776 (r2 ¼ 1 with rs12740374 in HapMap
CEU). cSNP associated with liver transcript level was rs2058804 (r2 ¼ 1 with rs2338014 in HapMap CEU).
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HDL2 and HDL3 cholesterol subfractions after chemical precipitation;
lipoprotein(a); and remnant lipoprotein cholesterol and triglycerides.
A visual summary of the patterns of association is provided in
Supplementary Figure 2 online. In several cases, we identified
stronger signals for specialized phenotypes, suggesting mechanistic
hypotheses. For example, the GCKR P446L allele (rs1260326) was
associated with increased concentrations of APOC-III (0.20 s.d. unit
increase per Leu allele; P ¼ 9  1012), an inhibitor of triglyceride
catabolism that is synthesized in the liver38.
For several loci, the strength of statistical evidence did not meet our
prespecified threshold of P o 5  108, but some of these loci may
represent true associations. For example, LPA coding SNP rs3798220
(I4399M, 2% minor allele frequency) was associated with LDL
cholesterol (P ¼ 3  107 after stages 1 and 2). In addition, in the
FHS, LPA rs3798220 was strongly associated with lipoprotein(a) level
(P ¼ 2  1049), with each copy of the minor C allele increasing
lipoprotein(a) level by a notable 1.8 s.d. units. These findings strongly
replicate a previous observation that 4399M allele carriers have higher
lipoprotein(a) concentrations39. This same SNP has also been shown
to increase risk for coronary artery disease, with the 4399M allele
estimated to increase risk by two- to threefold39. The association
between LPA I4399M and risk for coronary artery disease might be
mediated by elevated lipoprotein(a) and LDL cholesterol.
Allelic dosage and polygenic dyslipidemia
Having identified 30 loci, each with a modest effect, we next asked
whether the cumulative allelic dosage of risk alleles at these loci
contributes to the quantitative variation in lipoprotein levels seen in
the population. We modeled the allelic dosage in each individual in the
FHS second generation for the SNPs detailed in Table 2 (see Methods).
Mean lipoprotein concentration decreased (for HDL cholesterol) or
increased (for LDL cholesterol and triglycerides) in a stepwise fashion
across deciles of genotype score (Fig. 3; Po 1  10–45 for each trend).
The proportion of individuals exceeding clinical thresholds for ‘high’
or ‘low’ lipoprotein levels (HDL cholesterol o 40 mg/dl, LDL
cholesterol 4 160 mg/dl, or triglycerides 4 200 mg/dl, as defined
by the US national cholesterol treatment guidelines40) increased across
deciles of genotype score (Fig. 3; P o 1  10–15 for each trend).
Multiple independent common alleles at a locus
At each of the 30 identified loci, multiple independent common alleles
may contribute to trait variation. To identify additional associated
common SNPs at these loci, we repeated the genome-wide association
analysis in the seven stage 1 studies, including each of the index SNPs
in Table 2 as covariates. In contrast to our original meta-analysis, in
which 41,000 SNPs at 25 loci reached genome-wide significance
(Po 5  108), only 105 SNPs reached genome-wide significance in
this conditional analysis. These SNPs provided evidence for additional
HDL association signals in the CETP (peak SNP rs289714, P ¼ 2 
1025), LIPC (rs2070895, P ¼ 6  1016) and APOA1-APOC3-
APOA4-APOA5 (rs10892044, P ¼ 4  1010) loci; for additional
LDL association signals in the APOE-APOC1-APOC4-APOC2
(rs1985096, P ¼ 7  1017), LDLR (rs2738446, P ¼ 1  1011)
and ABCG8 (rs4953023, P ¼ 4  108) loci; and for additional
triglyceride signals in the LPL locus (rs894210, P ¼ 1  1010). After
combining the seven SNPs representing these independent signals with
those listed in Table 2, the proportion of variance explained in each
trait was 9.3% for HDL cholesterol, 7.7% for LDL cholesterol and
7.4% for triglycerides.
DISCUSSION
Using a GWAS and large-scale replication, we have convincingly
mapped 30 loci that contribute to variation in lipoprotein concentra-
tions in humans. These results suggest regions of the genome that
should be sequenced fully, as well as several new directions for
functional investigation and potential clinical applications.
Sequencing the positional candidate genes within the associated
intervals can help define the full spectrum of alleles that contribute to
lipoprotein concentrations and, in some cases, identify null alleles that
can provide clues to the in vivo consequences of loss of function41.
PCSK9, for example, was initially identified using linkage mapping,
and rare mutations with large effects (4100 mg/dl effect size) were
described42. Subsequent sequencing of PCSK9 revealed low-frequency
variants with more modest effects (such as PCSK9 R46L, 1%
frequency,B16 mg/dl effect size)43. The same group found nonsense
mutations in African-Americans, which proved that loss of PCSK9
function decreases LDL cholesterol41. In our study and a previous
one4, PCSK9 also harbored a common variant with an even more
modest effect (19% frequency, B3 mg/dl effect size). Thus, other
genes identified in our common variant screen may harbor
low-frequency variants and/or rare mutations that cause mendelian
syndromes. Deep sequencing of the new loci in population-
based samples and dyslipidemic families will be required to test
these hypotheses.
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Figure 3 Mean lipoprotein concentrations and proportion of individuals with low HDL cholesterol, high LDL cholesterol or high triglycerides, as a function
of allelic dosage score for HDL cholesterol, LDL cholesterol and triglycerides, respectively. Deciles of allelic dosage score are plotted on the x axis, and the
y axis represents either mean lipoprotein concentrations within that decile (gray bars) or the proportion of individuals within that decile who met clinical
criteria for ‘high’ or ‘low’ lipoprotein concentrations (black bars; cut points indicated in keys). Analyses were conducted for the following numbers of FHS
second-generation participants: 3,206 for HDL cholesterol, 3,090 for LDL cholesterol and 3,216 for triglycerides. The allelic dosage score comprised 32
SNPs from the 30 loci shown in Table 2. For SNPs associated with HDL cholesterol, we modeled the allele associated with lower HDL cholesterol. For SNPs
associated with LDL cholesterol or triglycerides, we modeled the allele associated with higher LDL cholesterol or higher triglycerides. Each of the six trends
was highly significant (P o 1015).
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Experimental manipulation of positional candidate genes in mice is
an alternate approach to define the consequences of gain or loss of
function. A variety of genetic techniques have been used to study
lipoprotein-related genes in animal models and cell culture. Because
lipoprotein metabolism is driven in large part by processes occurring
in the liver, delivery of genetic modifiers by vectors that are preferen-
tially taken up by liver can allow for analysis of the effects of genes on
lipid traits. For example, multiple groups have overexpressed PCSK9
in wild-type mouse liver through tail vein injections of recombinant
adenoviruses bearing the gene44–46; plasma LDL cholesterol was
significantly higher in mice receiving the PCSK9 vectors compared
to mice receiving control vectors. Our work provides several new
targets (TTC39B, for example) for such functional investigation.
Ultimately, with a full collection of DNA sequence variants in hand,
we may be able to test the hypothesis that these variants can help to
identify individuals at risk for cardiovascular disease and to better
target preventive interventions. As lipid genotypes have been shown to
add incremental information beyond plasma lipoprotein measure-
ments47,48, an allelic dosage score may allow for early identification
and treatment of at-risk individuals, before atherosclerosis becomes
advanced. Proving this hypothesis will require rigorous testing in
randomized clinical trials.
METHODS
Stage 1 study samples, phenotypes and genotyping. A full description of each
of the seven stage 1 studies is presented in Supplementary Methods. In each
study, LDL cholesterol was calculated using the Friedewald formula, with
missing values assigned to individuals with triglycerides 4400 mg/dl. Indivi-
duals known to be on lipid-lowering therapy were excluded from association
analysis for LDL cholesterol in all studies except the FHS. In the FHS,
we imputed the untreated LDL cholesterol values using an algorithm
described previously49.
All participants provided informed consent. Local ethical committees at each
participating institution approved the individual study protocols. The institu-
tional review boards at Boston Medical Center, Massachusetts Institute of
Technology and the University of Michigan approved this study.
Stage 1 genome-wide association analyses. In the FHS, we modeled pheno-
types in the following manner. We log-transformed triglyceride levels. To
account for potential confounding by population substructure within the FHS
sample (Americans of European ancestry), we used EIGENSTRAT software to
define principal components of ancestry. We inferred SNP weights for each
principal component using a subset of unrelated FHS individuals (n ¼ 882) and
then computed the principal component values for all others using the estimates
obtained from the unrelated subset. The first two principal components showed
gradients similar to those previously reported in individuals of European
ancestry (northwest, southeast and Ashkenazi Jewish; Supplementary Fig. 3
online). Several principal components were associated with LDL cholesterol, so
we adjusted for ten principal components in regression modeling.
For the second and third generations separately, we created sex-specific
residual lipoprotein concentrations after regression adjustment for age, age2
(age squared) and ten ancestry-informative principal components (mean age
across multiple visits and the square of this mean age were used for second-
generation participants). We standardized residuals to have a mean of 0 and s.d.
of 1. These generation- and sex-specific residual lipoprotein concentrations
served as the phenotypes in genotype-phenotype association analysis. Each
directly genotyped SNP was tested for association with lipid residuals, assuming
an additive mode of inheritance. To account for relatedness among two
generations of participants, we used linear mixed-effects models that specified
a fixed genotypic effect, a random polygenic effect allowing for residual
heritability and a variance-covariance structure accounting for familial correla-
tions50. The genomic control parameters in FHS were low, at 1.01, 1.03 and
1.02 (for LDL cholesterol, HDL cholesterol and triglycerides, respectively).
In the SUVIMAX, LOLIPOP and InCHIANTI GWASs, lipoprotein concen-
trations were adjusted for the effects of sex, age and age2. The SUVIMAX and
LOLIPOP samples did not include related individuals and were analyzed using
linear regression. The InCHIANTI GWAS included a small number of related
individuals and was analyzed using a variance component–based score test that
models background additive polygenic effects. In each case, an additive model
was used to model SNP effects.
Stage 1 imputation and meta-analysis for directly genotyped and
imputed SNPs. Genotype imputation and meta-analysis were carried out with
the MaCH and METAL packages, respectively. Details of imputation and
meta-analysis are described in Supplementary Methods.
Stage 2 study samples, phenotypes and genotyping. Replication of promising
association signals from stage 1 was attempted in up to 20,623 independent
participants from five stage 2 studies (Table 1). Fasting lipid concentrations
were available in each stage 2 study except ISIS; individuals known to be on
lipid-lowering therapy were excluded. The ISIS study participants were exam-
ined in the early 1990s, before lipid-lowering therapies became common, so no
exclusion based on drug therapy was necessary.
SNPs were genotyped using either the iPLEX Sequenom MassARRAY
platform or allelic discrimination on an ABI 7900 instrument (Applied
Biosystems). All genotyped SNPs had a genotyping call rate 495% on the
replication samples and had a Hardy-Weinberg equilibrium P 4 0.001.
We tested for association in each replication study using linear regression
adjusting for covariates as follows: age, age2, sex and diabetes status for the
MDC Cardiovascular Cohort (MDC-CC); age, age2 and sex for FINRISK97;
age, age2, sex, birth province in Finland and study group with analysis stratified
according to diabetes status for FUSION stage 2; age, age2 and diabetes status
for METSIM; and age, age2, sex, sex  age and sex  age2 with analysis
stratified according to myocardial infarction status for ISIS.
The statistical evidence from each stage 2 sample was combined with the
evidence from stage 1 using the fixed-effects z-statistic meta-analysis procedure
described above. A combined P o 5  108 was deemed significant based on
an estimated multiple testing burden equivalent to B1 million independent
common variants10.
SNP selection for stage 2 genotyping. We took forward SNPs into stage 2
primarily on the basis of P value in stage 1 after excluding SNPs from the 19
loci that had prior definitive association evidence3,4. We selected a set of
apparently independent SNPs by excluding SNPs with r2 4 0.2 or within a
distance of 1 Mb from other SNPs selected for follow-up genotyping. We
successfully genotyped and attempted, respectively, 66 and 70 SNPs in MDC-
CC, 60 and 64 SNPs in FINRISK97, 52 and 55 SNPs in FUSION stage 2, 52 and
53 SNPs in METSIM and 45 and 50 SNPs in ISIS. Different SNP lists were
genotyped in each study according to cost, constraints on the design of
multiplex assays and timing of SNP selections (some SNPs were selected based
on interim meta-analyses).
Variance-weighted meta-analysis. As an additional analysis, we applied
a uniform analysis strategy to all sample sets to estimate regression coefficients
(measuring association between each SNP and lipid levels) and their
corresponding standard errors and combined regression coefficients across
samples using an inverse variance-weighted meta-analysis (Supplemen-
tary Methods).
Definition of associated interval. For each index SNP in Table 2, we defined
the associated interval by first determining the set of HapMap SNPs in linkage
disequilibrium of r2 4 0.5 with the most significantly associated SNP. We then
bounded the associated interval by the flanking HapMap recombination
hotspots. These windows were likely to contain the causal polymorphisms
explaining the associations.
Specialized lipoprotein-related phenotypes, cis-expression quantitative trait
locus analyses and genotype score analysis in the FHS. Details for these are
described in the Supplementary Methods.
URLs. Association results of our meta-analysis of seven GWASs, http://www.
sph.umich.edu/csg/abecasis/public/lipids2008/; Markov chain haplotyping
package, http://www.sph.umich.edu/csg/abecasis/MACH; METAL meta-analysis
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tool for GWASs, http://www.sph.umich.edu/csg/abecasis/Metal/index.html;
EIGENSTRAT method for population stratification correction, http://genepath.
med.harvard.edu/~reich/Software.htm.
Note: Supplementary information is available on the Nature Genetics website.
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